Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Global Payments Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Global Payments Inc trades at $82.81 (market cap $21.46B). The key difference: Global Payments Inc is far larger — about 4.6× Definium Therapeutics Inc. Common Shares's market cap, and Global Payments Inc pays a 1.23% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Global Payments Inc for 50 Days on average.
| DFTX | GPN | |
|---|---|---|
Market Cap | $4.71B | $21.46B |
Volume | 1,966,636 | 1,482,600 |
Sector | Health | Financials |
52-Week High | $48.45 | $94.83 |
52-Week Low | $10.68 | $62.47 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $3.67B | $39.60B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Global Payments (GPN) trades at $82.77, up 1.2% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with strong gross margins (63.91%) but negative net income margin (-9.15%) and ROE (-4.09%). Recent news highlights Genius platform growth and Worldpay integration driving momentum, though rising costs and debt remain concerns. Cash flow trends show volatility with 2025 net cash flow of $6.38B but projected decline to $2.4B in 2026.
Analyst consensus remains bullish with 59% buy ratings and $102.75 price target, suggesting 24% upside. Key opportunities include digital payment expansion and margin improvements, while risks involve debt levels (debt-to-asset ratio 41.57% in 2025) and competitive pressures. The stock trades below book value (P/B 0.93) but at elevated P/E (38.43), requiring execution on growth initiatives to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
